These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22396600)

  • 21. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
    Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail.
    Durham ND; Yewdall AW; Chen P; Lee R; Zony C; Robinson JE; Chen BK
    J Virol; 2012 Jul; 86(14):7484-95. PubMed ID: 22553332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.
    Liu L; Wang W; Matz J; Ye C; Bracq L; Delon J; Kimata JT; Chen Z; Benichou S; Zhou P
    J Virol; 2016 Dec; 90(23):10642-10659. PubMed ID: 27654286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.
    Lai RP; Yan J; Heeney J; McClure MO; Göttlinger H; Luban J; Pizzato M
    PLoS Pathog; 2011 Dec; 7(12):e1002442. PubMed ID: 22194689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.
    Chakrabarti BK; Walker LM; Guenaga JF; Ghobbeh A; Poignard P; Burton DR; Wyatt RT
    J Virol; 2011 Aug; 85(16):8217-26. PubMed ID: 21653673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
    Klein JS; Gnanapragasam PN; Galimidi RP; Foglesong CP; West AP; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7385-90. PubMed ID: 19372381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
    Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
    Alam SM; Scearce RM; Parks RJ; Plonk K; Plonk SG; Sutherland LL; Gorny MK; Zolla-Pazner S; Vanleeuwen S; Moody MA; Xia SM; Montefiori DC; Tomaras GD; Weinhold KJ; Karim SA; Hicks CB; Liao HX; Robinson J; Shaw GM; Haynes BF
    J Virol; 2008 Jan; 82(1):115-25. PubMed ID: 17942537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. V4 region of the HIV-1 envelope gene mediates immune escape and may not promote the development of broadly neutralizing antibodies.
    Ji Y; Han X; Tian W; Gao Y; Jin S; Zhang L; Shang H
    Vaccine; 2018 Nov; 36(50):7700-7707. PubMed ID: 30389191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
    Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
    EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.
    Diomede L; Nyoka S; Pastori C; Scotti L; Zambon A; Sherman G; Gray CM; Sarzotti-Kelsoe M; Lopalco L
    J Virol; 2012 Apr; 86(8):4129-38. PubMed ID: 22301151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.